Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Recent & Breaking News (TSXV:TLT)

Theralase Announces Management Information Circular and Annual General Meeting Postponement Due to COVID-19

Accesswire June 30, 2020

The Top Healthcare Bullboards: April - June 2020

Stockhouse Editorial June 17, 2020

Theralase Release 1Q2020 Financial Statements

Accesswire May 29, 2020

Massive FDA Green Light for Leading Bladder Cancer Solution

Omri Wallach May 26, 2020

Theralase Receives FDA IND Authorization

Accesswire May 19, 2020

Theralase Announces Warrant Extension

Accesswire May 11, 2020

Theralase Releases 2019 Financial Results

Accesswire April 29, 2020

Theralase Releases Quarterly Newsletter

Accesswire April 21, 2020

The Top Healthcare Bullboards: Jan - Mar 2020

Stockhouse Editorial March 23, 2020

Theralase Provides Company Update on Phase II Bladder Cancer Clinical Study

Accesswire March 20, 2020

Advanced Research to Answer Multibillion Dollar Bladder Cancer Problem

Stockhouse Editorial February 28, 2020

Theralase Advances Its Pivotal Phase II Non-Muscle Invasive Bladder Cancer Study with a New Clinical Study Site in Nova Scotia

Accesswire February 25, 2020

Theralase Technologies Awarded 2020 TSX Venture 50

Accesswire February 20, 2020

Theralase Granted US Patent for Multiwavelength Photodynamic Therapy

Accesswire January 27, 2020

Theralase Wins Precedent-Setting Lawsuit Against Anonymous Individuals for Posting Defamatory Comments Online

Accesswire January 16, 2020

View from the C-Suite: Shawn Shirazi, Chief Executive Officer, Theralase Technologies Inc., tells his company's story. Filmed on December 18, 2019

Canada NewsWire January 8, 2020

Theralase Releases Quarterly Newsletter

Accesswire January 7, 2020

Theralase Releases Third Quarter 2019 Financial Results and Company Update

Accesswire November 29, 2019

Theralase Researchers Receive Recognition for Recent Scientific Publications

Accesswire November 27, 2019

Theralase Announces Leadership Transition

Accesswire October 31, 2019